Account
Insider Insights
08.07.2024
New German Medicines Research Act: confidential re...

Germany's new Medicines Research Act allows confidential rebates for pharma companies, but recent am...

Read more
Insider Insights
04.07.2024
Hemgenix becomes the first treatment to enter NHS ...

New ground-breaking gene therapy for haemophilia B enters NHS England's Innovative Medicines Fund, o...

Read more
Insider Insights
03.07.2024
The transformation of healthcare through personali...

The rise of personalised medicine is revolutionizing healthcare, prompting a re-evaluation of tradit...

Read more
Insider Insights
17.06.2024
Health Technology Assessment: HTACG provide update...

We discuss the updates on EU HTA from the June meeting of the Member State Coordination Group on Hea...

Read more
Insider Insights
12.06.2024
Scotland leads the UK in approving Mounjaro for ob...

Scottish Medicines Consortium approves the use of obesity treatment under the NHS in UK first, whils...

Read more
Insider Insights
30.05.2024
NICE and NHS England unveil plan to facilitate qui...

NHS and NICE propose faster adoption of MedTech, streamlining funding and market access for innovati...

Read more
Insider Insights
21.05.2024
The Bundesrat rejected confidential rebates propos...

The German government’s proposal to keep negotiated confidential rebates was rejected by the feder...

Read more
Insider Insights
01.05.2024
Ground-breaking decision: first medicine ever with...

NHS takes a bold step towards achieving net zero by decommissioning desflurane due to its high globa...

Read more
Insider Insights
23.04.2024
NICE Approves CAR-Therapy for NHS

NICE recommends Kymriah® for routine NHS use, offering immense benefits for those with resistant B-...

Read more
Insider Insights
07.03.2024
EU releases draft act on Joint Clinical Assessment...

Consultation launched on EU draft Regulation for joint clinical assessments, seeking feedback to imp...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.